APA (7th ed.) Citation

A, F., SE, N., PD, T., PJ, S., DP, N., & CM, G. (2025). Comparison of the in vivo efficacy and resistance development potential between cefiderocol and ceftolozane/tazobactam human simulated exposures against Pseudomonas aeruginosa in 72-hour murine thigh infection model. Infectious diseases (London, England), 57(7), 658. https://doi.org/10.1080/23744235.2025.2471822

Chicago Style (17th ed.) Citation

A, Fouad, Nicolau SE, Tamma PD, Simner PJ, Nicolau DP, and Gill CM. "Comparison of the in Vivo Efficacy and Resistance Development Potential Between Cefiderocol and Ceftolozane/tazobactam Human Simulated Exposures Against Pseudomonas Aeruginosa in 72-hour Murine Thigh Infection Model." Infectious Diseases (London, England) 57, no. 7 (2025): 658. https://doi.org/10.1080/23744235.2025.2471822.

MLA (9th ed.) Citation

A, Fouad, et al. "Comparison of the in Vivo Efficacy and Resistance Development Potential Between Cefiderocol and Ceftolozane/tazobactam Human Simulated Exposures Against Pseudomonas Aeruginosa in 72-hour Murine Thigh Infection Model." Infectious Diseases (London, England), vol. 57, no. 7, 2025, p. 658, https://doi.org/10.1080/23744235.2025.2471822.